Table 1.

The outcomes of different clinical trials on the use of H. pylori eradication therapies and their effect on the microbiota at the gastric and gut levels.

Authors, Year	Patient Population	Outcomes	References
Fabian Frost et al., 2019	- 212 H. pylori (+) - 212 H. pylori (−)	↑ alpha diversity, ↑ Prevotella, ↑ Bacteroidetes, ↑ Parasutterella, ↑ Holdemanella, ↑ Betaproteobacteria, ↑ Pseudoflavonifractor, ↑ Alisonella, ↑ Howardella	[70]
Chen et al., 2018	- 70 H. pylori-positive - 35 H. pylori-negative	↑ alpha diversity	[71]
Nihar Ranjan Dash et al., 2019	- 60 H. pylori (+)	↑ Succinivibrio, ↑ Coriobacteriaceae, ↑ Enterococcaceae, ↑ Rikenellaceae, ↑ Candida glabrata	[72]
Juan-Juan Gao et al., 2018	- 24 H. pylori (+) - 15 H. pylori (−) - 8 with past infection	- Post-infection group: ↓ Bacteroidetes, ↓ Parabacteroides, ↓ Barnesiella, ↑ Firmicutes, ↑ Proteobacteria, ↑ Faecalibacterium - Current infection group: same shifts but lower amounts	[73]
Sun et al., 2024	Population with cerebral infarction - H. pylori (+) - H. pylori (−)	↓ Proteobacteria, ↓ Verrucomicrobia, ↓ Akkermansia muciniphila, ↓ Bacteroides dorei, ↓ Fusobacterium ulcerans, ↑ Megamonas funiformis, ↑ Bifidobacterium adolescentis	[74]
Iino et al., 2020	- 884 subjects with H. pylori infection	↑ Lactobacilli	[75]
He et al., 2019	- 10 asymptomatic adults with H pylori-related gastritis treated with BQT for 14 days - 7 age-matched adults as healthy controls	- After treatment: ↓ alpha diversity, ↓ beta diversity	[76]
Martin-Nuñez et al., 2019	- Controls - H. pylori (+) pre-eradication - H. pylori (+) treated	- After treatment: ↓ Firmicutes, ↓ Actinobacteria, ↓ Proteobacteria, ↓ Verrucomicrobia, ↑ Proteobacteria - Pre-eradication: same shifts but in lower amounts	[77]